Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...
This page details the projects that were awarded funding as part of Phase 4 of the Evaluation Accelerator Fund (EAF). BackgroundIn March 2025, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback